NVO250110P111000
- 11.10
- 0.000.00%
Novo-Nordisk A/S Newsroom
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Euro Stocks Can Offer a Lesson in High Concentration for the U.S. – Goldman
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge -- Barrons.com
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Correction to Novo Nordisk, Valo Health Article on Wednesday
Novo-Nordisk A/S expands its cooperation with Valo Health to develop weight loss medications using AI.
On January 9, Glorix reported that Novo-Nordisk A/S and the USA technology company Valo Health agreed to expand their collaboration agreement to develop up to 11 drugs in 2023, utilizing human data and AI to develop up to 20 new therapies targeting obesity, type 2 diabetes, and cardiovascular diseases. According to the terms of the extended agreement, Valo is entitled to receive a total of up to $0.19 billion in short-term payments and about $4.6 billion in development milestone payments.
Donald Trump Wants Tariffs on Denmark Next. These Industries Would Be Hit Most. -- Barrons.com
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk Analyst Ratings
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
Novo Nordisk's CagriSema Selloff Is Overdone, UBS Says -- Market Talk
Novo-Nordisk A/S (NVO.US) expands its collaboration with Valo Health with a massive investment of 4.6 billion USD to co-develop new cardiac metabolism medications.
The Danish pharmaceutical giant Novo-Nordisk A/S announced on Wednesday an expansion of its collaboration with the AI biotechnology company Valo Health, aiming to accelerate the development of new therapies for cardiometabolic diseases.
Novo Nordisk Shares Are Trading Higher After the Company Entered Into an Expanded Agreement With Valo Health to Discover and Develop Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease.
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
Ozempic Maker Novo Nordisk, After Trial Disappointment, Expands AI Deal in Potential $4.6 Billion Pact
Facebook Moderation Move Is a Mistake. Why -2-
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
Novo Nordisk Target Cut to DKK750 From DKK1,100 by UBS